Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Zenz, S; Regittnig, W; Boulgaropoulos, B; Augustin, T; Brunner, M; Korsatko, S; Münzker, J; Narath, SH; Raml, R; Magnes, C; Pieber, TR.
Effect of Liraglutide Treatment on Whole-body Glucose Fluxes in C-peptide-Positive Type 1 Diabetes During Hypoglycemia.
J Clin Endocrinol Metab. 2022; 107(9):e3583-e3593 Doi: 10.1210/clinem/dgac369
Web of Science PubMed FullText FullText_MUG

 

Leading authors Med Uni Graz
Pieber Thomas
Zenz Sabine
Co-authors Med Uni Graz
Boulgaropoulos Beate
Brunner Martina
Korsatko Stefan
Münzker Julia
Narath Sophie Helene
Regittnig Werner
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
CONTEXT: The effect of liraglutide in C-peptide-positive (C-pos) type 1 diabetes (T1D) patients during hypoglycemia remains unclear. OBJECTIVE: To investigate the effect of a 12-week liraglutide treatment on the body glucose fluxes during a hypoglycemic clamp in C-pos T1D patients and its impact on the alpha- and beta-cell responses during hypoglycemia. DESIGN: This was a randomized, double-blind, crossover study. Each C-pos T1D patient was allocated to the treatment sequence liraglutide/placebo or placebo/liraglutide with daily injections for 12 weeks adjunct to insulin treatment, separated by a 4-week washout period. SETTING AND PARTICIPANTS: Fourteen T1D patients with fasting C-peptide ≥ 0.1 nmol/L. INTERVENTION(S): All patients underwent a hyperinsulinemic-stepwise-hypoglycemic clamp with isotope tracer [plasma glucose (PG) plateaus: 5.5, 3.5, 2.5, and 3.9 mmol/L] after a 3-month liraglutide (1.2 mg) or placebo treatment. MAIN OUTCOME MEASURE(S): The responses of endogenous glucose production (EGP) and rate of peripheral glucose disposal (Rd) were similar for liraglutide and placebo treatment during the clamp. RESULTS: The numbers of hypoglycemic events were similar in both groups. At the clamp, mean glucagon levels were significantly lower at PG plateau 5.5 mmol/L in the liraglutide than in the placebo group but showed similar responses to hypoglycemia in both groups. Mean C-peptide levels were significantly higher at PG-plateaus 5.5 and 3.5 mmol/L after liraglutide treatment, but this effect was not reflected in EGP and Rd. Hemoglobin A1c and body weight were lower, and a trend for reduced insulin was seen after liraglutide treatment. CONCLUSIONS: The results indicate that 3 months of liraglutide treatment does not promote or prolong hypoglycemia in C-pos T1D patients.

Find related publications in this database (Keywords)
type 1 diabetes
hypoglycemia
liraglutide
beta-cell function
GLP-1 analogue
clinical trial
© Med Uni Graz • Imprint